Polyrizon

Executive Summary

Polyrizon is an Israeli biotech company pioneering intranasal drug delivery technologies with its Capture & Contain (C&C) and Trap & Target (T&T) platforms. Founded in 2020 and headquartered in Raanana, the company is developing non-invasive, rapid administration methods for a range of therapeutics, potentially improving patient compliance and enabling novel treatments for conditions such as neurological disorders, infectious diseases, and vaccine delivery. Currently in the preclinical stage, Polyrizon is focused on validating its technology and advancing its lead candidates toward IND-enabling studies. The company's innovative approach addresses key challenges in intranasal delivery, including overcoming mucosal barriers and ensuring targeted drug release, which could unlock significant market opportunities in the multibillion-dollar drug delivery sector. Despite being at an early stage, Polyrizon's proprietary platforms have attracted attention for their versatility and potential to enhance the efficacy of existing drugs. The company is actively progressing its candidate pipeline, with a focus on securing strategic partnerships and advancing toward clinical trials. Given the strong unmet need for non-invasive delivery options and the platform's broad applicability, Polyrizon is well-positioned to capture value in the biotech landscape. However, execution risks remain typical for preclinical-stage companies, including regulatory hurdles and capital requirements for further development.

Upcoming Catalysts (preview)

• Q2 2027Completion of IND-enabling GLP toxicology studies for lead asset70% success
• Q4 2026Strategic partnership or licensing deal for CNS or vaccine indication60% success
• Q1 2027Publication of preclinical efficacy data in a peer-reviewed journal80% success